- Home
- ITRM vs HAS Comparison
ITRM vs HAS Comparison
Compare ITRM & HAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRM
- HAS
- Stock Information
- Founded
- ITRM 2015
- HAS 1923
- Country
- ITRM Ireland
- HAS United States
- Employees
- ITRM N/A
- HAS N/A
- Industry
- ITRM Biotechnology: Pharmaceutical Preparations
- HAS Recreational Games/Products/Toys
- Sector
- ITRM Health Care
- HAS Consumer Discretionary
- Exchange
- ITRM Nasdaq
- HAS Nasdaq
- Market Cap
- ITRM 37.7M
- HAS N/A
- IPO Year
- ITRM 2018
- HAS N/A
- Fundamental
- Price
- ITRM $1.08
- HAS $52.65
- Analyst Decision
- ITRM Strong Buy
- HAS Strong Buy
- Analyst Count
- ITRM 1
- HAS 8
- Target Price
- ITRM $5.00
- HAS $80.50
- AVG Volume (30 Days)
- ITRM 300.3K
- HAS 2.1M
- Earning Date
- ITRM 05-12-2025
- HAS 04-24-2025
- Dividend Yield
- ITRM N/A
- HAS 5.32%
- EPS Growth
- ITRM N/A
- HAS N/A
- EPS
- ITRM N/A
- HAS 2.75
- Revenue
- ITRM N/A
- HAS $4,135,500,000.00
- Revenue This Year
- ITRM N/A
- HAS $1.87
- Revenue Next Year
- ITRM $150.10
- HAS $5.36
- P/E Ratio
- ITRM N/A
- HAS $19.15
- Revenue Growth
- ITRM N/A
- HAS N/A
- 52 Week Low
- ITRM $0.81
- HAS $49.00
- 52 Week High
- ITRM $3.02
- HAS $73.46
- Technical
- Relative Strength Index (RSI)
- ITRM 32.84
- HAS 39.42
- Support Level
- ITRM $1.05
- HAS $51.33
- Resistance Level
- ITRM $1.16
- HAS $53.69
- Average True Range (ATR)
- ITRM 0.08
- HAS 3.02
- MACD
- ITRM -0.00
- HAS -0.35
- Stochastic Oscillator
- ITRM 13.04
- HAS 26.24
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.